Detalhe da pesquisa
1.
RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
; 132(20): 2154-2165, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181174
2.
Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma.
Br J Haematol
; 184(6): 999-1005, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30560573
3.
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
Br J Haematol
; 196(4): e33-e37, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34636043
4.
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
Br J Haematol
; 193(3): e19-e22, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33715154
5.
Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial.
Leuk Lymphoma
; 60(9): 2291-2294, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30773077
6.
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.
Amyloid
; 24(4): 242-244, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28984490